Microsoft word - cv-ultrashort1page2012uk_inclpubl.doc

C V ( S H O R T ) H E N N I N G B E C K - N I E L S E N
Professor Henning Beck-Nielsen, MD, DMSc Odense University Hospital, Department of Endocrinology, Kloevervaenget 6, 4th floor, 5000 Odense C, Denmark28 June 1945
Henning Beck-Nielsen (HBN) is Professor of Endocrinology at the University of Southern Denmark and
Consultant and Head of research at Odense University Hospital. He has been specialising in diabetes for the past
30 years. HBN has a high international reputation for his scientific work and has received a number of
acknowledgements and awards.

Current positions
Professor of Endocrinology, Faculty of Health Sciences, University of Southern Denmark, Odense
Consultant, Department of Endocrinology, Odense University Hospital
Head of the Endocrine Research Unit (EFE), Odense University Hospital/University of Southern Denmark

Education and training (selected)
1985
Specialist of medical endocrinology (medical hormonal diseases) Specialist of internal medicine (medical diseases) Doctor of medical science: Insulin receptors in man. The monocyte as model for insulin receptor studies in man, defended at the Aarhus University, Denmark, 12 September 1980 Diploma of doctor of medicine, Aarhus University, grade 10.3 (Danish 13-scale)
Doctoral and PhD assessments
Official opponent of 18 dissertations (1984-2012): 7 at the University of Copenhagen, Denmark, 6 at the
University of Southern Denmark, Odense, Denmark, 3 at the University of Aarhus, Denmark, 1 at the University of
Oslo, Norway, and 1 at the University of Helsinki, Finland. Assessor of 14 PhD theses (1993-2012).

Supervision of junior researchers
Terminated theses at EFE under my supervision: 7 doctoral dissertations, 30 PhD theses and 6 diploma theses.
Currently supervisor for 8 PhD students.
Scientific publications
The scientific production comprises 423 original papers in total, including 25 book chapters. ISI Web of Science
indicates 552 publications, including abstracts, cited more than 12,000 times. h-index 61. HBN has given approx.
370 lectures, of which approx. 255 as invited lecturer.
Selected publications
Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. Sequence of events
leading to non-insulin-dependent diabetes mellitus. J Clin Invest 1994 Nov;94(5):1714-21.
Beck-Nielsen H. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients: response to davidson and mikhail. Diabetes Care 2004 Jul;27(7):1847-8. Ling C, Poulsen P, Carlsson E, Ridderstrale M, Almgren P, Wojtaszewski J, et al. Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins. J Clin Invest 2004 Nov;114(10):1518-26. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009 Jun 20;373(9681):2125-35. Vind BF, Pehmoller C, Treebak JT, Birk JB, Hey-Mogensen M, Beck-Nielsen H, et al. Impaired insulin-induced site-specific phosphorylation of TBC1 domain family, member 4 (TBC1D4) in skeletal muscle of type 2 diabetes patients is restored by endurance exercise-training. Diabetologia 2011 Jan;54(1):157-67. E - M A I L : H E N N I N G . B E C K - N I E L S E N @ O U H . R E G I O N S Y D D A N M A R K . D K T E L . + 4 5 6 5 4 1 3 4 4 4 ∗ M O B I L E 6 0 1 6 4 0 6 5 ∗ F A X + 4 5 6 5 9 1 9 6 5 3

Source: http://www.ouh.dk/dwn269376.pdf

A list of options to manage osteosarcoma

MANAGING CANINE BONE CANCER (OSTEOSARCOMA) Approximately 10,000 dogs a year are diagnosed with bone cancer. Early signs include persistent limp, swelling over a bone, etc or can manifest by change in activity, decreased appetite, etc. It's good to check over your dog and point out any unusual bony changes or swelling you may see. This type of cancer can involve long bones, ribs, jaw bones,

02

ELŐADÁSOK NYOMDAKÉSZ ANYAGA SPAMBIZNISZ – A KÉRETLEN LEVELEK ÚTJA A TÁMADÓTÓL AZ ÁLDOZATIG Krasznay Csaba, Bevezetés Napjaink legnagyobb kihívásai közé tartozik a kéretlen elektronikus levelek kezelése. Az iparági statisztikák alapján elmondható, hogy az összes elküldött e-mail kb. 40%-a tartozik ebbe a körbe, ami naponta több mint 10 milliárd

Copyright © 2018 Medical Abstracts